One of the most important things a patient can do is see a true MPN Specialist, the … Learn More
Impact of Anti-Endothelial Cell Antibodies in Patients with Polycythemia Vera and Thrombosis
Physicians should consider measuring anti-endothelial cell antibodies in patients with polycythemia vera, the investigators suggested. A new analysis of anti-endothelial cell antibodies (AECAs) in patients with polycythemia vera (PV) suggests that autoimmunity may be one mechanism by which thrombosis develops. Abstract Polycythemia vera (PV) causes thrombosis. Erythrocytosis and cell adhesiveness are responsible for thrombosis. JAK2V617F causes inflammation […]
Lifestyle, Environmental and Host Factors in the development of MPN
Abstract Philadelphia-negative myeloproliferative neoplasms (MPNs) occur when there is over-production of myeloid cells stemming from hematopoietic stem cells with constitutive activation of JAK/STAT signaling, with JAK2V617F being the most commonly occurring somatic driver mutation. Chronic inflammation is a hallmark feature of MPNs and it is now evident that inflammation is not only a symptom of MPN but […]
What constitutes disease modification in myelofibrosis?
Abstract The development of targeted therapies for the treatment of myelofibrosis highlights a unique issue in a field that has historically relied on symptom relief, rather than survival benefit or modification of disease course, as key response criteria. There is, therefore, a need to understand what constitutes disease modification of myelofibrosis to advance appropriate drug […]
Curcumin Induces Cell Death in JAK2 Mutated Cells by Inhibition of JAK2/STAT and mTORC1 Pathways
Publisher’s Note by David Wallace: The two studies below provide compelling data on the effectiveness of supplementation with curcumin in patients with MPN. Although no recent studies on curcumin have emerged in MPN (since 2019), it would seem prudent to discuss the supplement with your physician. Naturally if you are taking any type of blood […]
MPN Clinical Trials, 2022 Update
MPN Clinical Trial update with Dr. Abu-Zeinah, from ASH 2021 by David Wallace TRANSCRIPT | MPN Clinical Trials, 2022 Update David Wallace: Hello, I’m David Wallace, founder of PV Reporter and our nonprofit organization MPN Cancer Connection. And your host for today’s program, the American Society of Hematology 2021 update, is Dr. Ghaith Abu-Zeinah from […]
- 1
- 2
- 3
- …
- 34
- Next Page »
